These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14607760)

  • 21. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.
    Yin J; Wei J; Xu JH; Xiao Y; Zhang YC
    Acta Haematol; 2014; 131(2):114-25. PubMed ID: 24158006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas.
    Usui N; Yano S; Asai O; Dobashi N; Osawa H; Takei Y; Sugiyama K; Takahara S; Otubo H; Saito T; Okawa Y; Hagino T; Kaito K; Kobayashi M
    Clin Lymphoma; 2005 Jun; 6(1):31-6. PubMed ID: 15989704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
    Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
    Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
    Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
    Kewalramani T; Zelenetz AD; Hedrick EE; Donnelly GB; Hunte S; Priovolos AC; Qin J; Lyons NC; Yahalom J; Nimer SD; Moskowitz CH
    Blood; 2000 Oct; 96(7):2399-404. PubMed ID: 11001890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
    Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
    Baldissera RC; Nucci M; Vigorito AC; Maiolino A; Simões BP; Lorand-Metze I; Aranha FJ; Miranda EC; Pagnano KB; Ruiz MA; Moraes AA; De Souza CA
    Acta Haematol; 2006; 115(1-2):15-21. PubMed ID: 16424644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
    Bertz H; Zeiser R; Lange W; Fetscher S; Waller CF; Finke J
    Ann Oncol; 2004 Sep; 15(9):1419-24. PubMed ID: 15319249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversies in the treatment of lymphoma with autologous transplantation.
    Moskowitz AJ; Moskowitz CH
    Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Salvage therapy in relapsed or refractory malignant lymphoma].
    Kashimura T; Murohashi I
    Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
    Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.